Drug firm FDC launches stronger versions of Favipiravir at Rs 160 per tablet in India
The 800 mg version of the drugs will help reduce the number of tablets to be taken by any patient by 75 percent, it added.
New Delhi: Drug firm FDC Ltd on Friday said it has launched stronger versions of its Favipiravir brands, PiFLU and Favenza, used to treat mild-to-moderate cases of COVID-19, at a price of Rs 160 per tablet in India. These prescription-only drugs will be available at all retail medical outlets and hospital pharmacies across the country, from November 1, 2020, FDC said in a BSE filing.The 800...
New Delhi: Drug firm FDC Ltd on Friday said it has launched stronger versions of its Favipiravir brands, PiFLU and Favenza, used to treat mild-to-moderate cases of COVID-19, at a price of Rs 160 per tablet in India.
These prescription-only drugs will be available at all retail medical outlets and hospital pharmacies across the country, from November 1, 2020, FDC said in a BSE filing.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd